

**PROPOSED AMENDMENTS TO
A-ENGROSSED SENATE BILL 71**

1 On page 1 of the printed A-engrossed bill, line 2, after “provisions;” delete
2 the rest of the line and insert “amending ORS 192.502, 431.964 and 431.996;
3 and declaring an emergency.”.

4 On page 2, after line 11, insert:

5 **“SECTION 2.** ORS 431.966 is amended to read:

6 “431.966. (1)(a) Except as provided under subsection (2) of this section,
7 prescription monitoring information submitted under ORS 431.964 to the
8 prescription monitoring program established in ORS 431.962:

9 “(A) Is protected health information under ORS 192.553 to 192.581.

10 “(B) Is not subject to disclosure pursuant to ORS 192.410 to 192.505.

11 “(b) Except as provided under subsection [(2)(a)(E)] **(2)(a)(F)** of this sec-
12 tion, prescription monitoring information submitted under ORS 431.964 to the
13 prescription monitoring program may not be used to evaluate a practitioner’s
14 professional practice.

15 “(2)(a) To the extent that the law or regulation is applicable to the pre-
16 scription monitoring program, if a disclosure of prescription monitoring in-
17 formation, other than the sex of a patient for whom a drug was prescribed,
18 complies with the federal Health Insurance Portability and Accountability
19 Act of 1996 (P.L. 104-191) and regulations adopted under it, including 45
20 C.F.R. parts 160 and 164, federal alcohol and drug treatment confidentiality
21 laws and regulations [*adopted under those laws*], including 42 C.F.R. part 2,
22 and state health and mental health confidentiality laws, including ORS

1 179.505, 192.517 and 192.553 to 192.581, the Oregon Health Authority shall
2 disclose the information:

3 “(A) To a practitioner or pharmacist, or, if a practitioner or pharmacist
4 authorizes the authority to disclose the information to a member of the
5 practitioner’s or pharmacist’s staff, to a member of the practitioner’s or
6 pharmacist’s staff. If a practitioner or pharmacist authorizes disclosing the
7 information to a member of the practitioner’s or pharmacist’s staff under this
8 subparagraph, the practitioner or pharmacist remains responsible for the use
9 or misuse of the information by the staff member. To receive information
10 under this subparagraph, or to authorize the receipt of information by a staff
11 member under this subparagraph, a practitioner or pharmacist must certify
12 that the requested information is for the purpose of evaluating the need for
13 or providing medical or pharmaceutical treatment [*for*] **to** a patient to whom
14 the practitioner or pharmacist anticipates providing, is providing or has
15 provided care.

16 “(B) **To a practitioner or pharmacist as part of an automated sys-**
17 **tem integrated into the prescription monitoring program by the au-**
18 **thority. An automated system integrated into the prescription**
19 **monitoring program under this subparagraph may disclose informa-**
20 **tion only for the purposes of notifying a practitioner or pharmacist**
21 **of a potentially dangerous drug interaction or of multiple practitioners**
22 **prescribing drugs to a patient.**

23 “[*B*] (C) To a practitioner in a form that catalogs all prescription drugs
24 prescribed by the practitioner according to the number assigned to the
25 practitioner by the Drug Enforcement Administration of the United States
26 Department of Justice.

27 “[*C*] (D) To designated representatives of the authority or any vendor
28 or contractor with whom the authority has contracted to establish or main-
29 tain the electronic system of the prescription monitoring program.

30 “[*D*] (E) Pursuant to a valid court order based on probable cause and

1 issued at the request of a federal, state or local law enforcement agency en-
2 gaged in an authorized drug-related investigation involving a person to
3 whom the requested information pertains.

4 “[*E*] (F) To a health professional regulatory board that certifies in
5 writing that the requested information is necessary for an investigation re-
6 lated to licensure, **licensure** renewal or a disciplinary action involving the
7 applicant, licensee or registrant to whom the requested information pertains.

8 **“(G) To the State Medical Examiner or designee of the State Med-
9 ical Examiner, a district medical examiner appointed under ORS
10 146.065 or a deputy medical examiner appointed under ORS 146.085, for
11 the purpose of conducting a medicolegal investigation or autopsy.**

12 “[*F*] (H) To a prescription monitoring program of another state if the
13 confidentiality, security and privacy standards of the requesting state are
14 determined by the authority to be equivalent to those of the authority.

15 “[*G*] *To the State Medical Examiner or designee of the State Medical Ex-
16 aminer, for the purpose of conducting a medicolegal investigation or autopsy.*]

17 “(b) The authority may disclose information from the prescription moni-
18 toring program that does not identify a patient, practitioner or drug outlet:

19 “(A) For educational, research or public health purposes;

20 “(B) To a local public health authority, as defined in ORS 431.260; or

21 “(C) To officials of the authority who are conducting special
22 epidemiologic morbidity and mortality studies in accordance with ORS
23 413.196 and rules adopted under ORS 431.110.

24 “(c) The authority shall disclose information relating to a patient main-
25 tained in the electronic system operated pursuant to the prescription moni-
26 toring program [*established under ORS 431.962*] to that patient at no cost to
27 the patient within 10 business days after the authority receives a request
28 from the patient for the information.

29 “(d)(A) A patient may request the authority to correct any information
30 about the patient that is erroneous. The authority shall grant or deny a re-

1 quest to correct information within 10 business days after the authority re-
2 ceives the request.

3 “(B) If the authority denies a patient’s request to correct information
4 under this paragraph, or fails to grant a patient’s request to correct infor-
5 mation under this paragraph within 10 business days after the authority re-
6 ceives the request, the patient may appeal the denial or failure to grant the
7 request. Upon [*receipt*] **receiving notice** of an appeal under this subpara-
8 graph, the authority shall conduct a contested case hearing as provided in
9 ORS chapter 183. Notwithstanding ORS 183.450, [*in the contested case hear-*
10 *ing,*] the authority has the burden **in the contested case hearing** of estab-
11 lishing that the information included in the prescription monitoring program
12 is correct.

13 “(e) The information in the prescription monitoring program may not be
14 used for any commercial purpose.

15 “(f) In accordance with ORS 192.553 to 192.581 and federal privacy regu-
16 lations, any person authorized to prescribe or dispense a prescription drug
17 and who is entitled to access a patient’s prescription monitoring information
18 may discuss or release the information to other health care providers in-
19 volved with the patient’s care[, *in order to provide*] **for the purpose of**
20 **providing** safe and appropriate care coordination.

21 “(3)(a) The authority shall maintain records of the information disclosed
22 through the prescription monitoring program including, but not limited to:

23 “(A) The identity of each person who requests or receives information
24 from the program and [*the organization, if any,*] **any organization that** the
25 person represents;

26 “(B) The information released to each person or organization; and

27 “(C) The date and time the information was requested and the date and
28 time the information was provided.

29 “(b) Records maintained as required by this subsection may be reviewed
30 by the Prescription Monitoring Program Advisory Commission.

1 “(4) Information in the prescription monitoring program that identifies
2 an individual patient must be removed no later than three years from the
3 date the information is entered into the program.

4 “(5) The authority shall notify the Attorney General and each affected
5 individual of an improper disclosure of information from the prescription
6 monitoring program.

7 “(6)(a) If the authority or a person or entity required to report or au-
8 thorized to receive or release controlled substance prescription information
9 under this section violates this section or ORS 431.964 or 431.968, a person
10 injured by the violation may bring a civil action against the authority, per-
11 son or entity and may recover damages in the amount of \$1,000 or actual
12 damages, whichever is greater.

13 “(b) Notwithstanding paragraph (a) of this subsection, the authority and
14 a person or entity required to report or authorized to receive or release
15 controlled substance prescription information under this section are immune
16 from civil liability for violations of this section or ORS 431.964 or 431.968
17 unless the authority, person or entity acts with malice, criminal intent, gross
18 negligence, recklessness or willful intent.

19 “(7) Nothing in ORS 431.962 to 431.978 and 431.992 requires a practitioner
20 or pharmacist who prescribes or dispenses a prescription drug to obtain in-
21 formation about a patient from the prescription monitoring program. A
22 practitioner or pharmacist who prescribes or dispenses a prescription drug
23 may not be held liable for damages in any civil action on the basis that the
24 practitioner or pharmacist [*did or did not request or obtain*] **requested or**
25 **obtained** information from the prescription monitoring program.”.

26 In line 12, delete “2” and insert “3”.

27 On page 8, line 36, delete “3” and insert “4”.

28 After line 37, insert:

29 **“SECTION 5. Before the Oregon Health Authority may implement**
30 **an automated system integrated into the prescription monitoring pro-**

1 **gram as described in ORS 431.966 (2)(a)(B), the automated system must**
2 **successfully complete a testing process to ensure that the automated**
3 **system is capable of successfully notifying a practitioner or**
4 **pharmacist for the purposes described in ORS 431.966 (2)(a)(B) without**
5 **a high rate of error.**

6 **“SECTION 6. The amendments to ORS 431.966 by section 2 of this**
7 **2015 Act apply to information related to prescription drugs classified**
8 **in schedules II through IV that are dispensed before, on or after the**
9 **operative date specified in section 7 of this 2015 Act.**

10 **“SECTION 7. (1) The amendments to ORS 431.964 and 431.966 by**
11 **sections 1 and 2 of this 2015 Act become operative on January 1, 2016.**

12 **“(2) The Oregon Health Authority may take any action before the**
13 **operative date specified in subsection (1) of this section that is neces-**
14 **sary to enable the authority to exercise, on and after the operative**
15 **date specified in subsection (1) of this section, all the duties, powers**
16 **and functions conferred on the authority by the amendments to ORS**
17 **431.964 and 431.966 by sections 1 and 2 of this 2015 Act.**

18 **“SECTION 8. This 2015 Act being necessary for the immediate**
19 **preservation of the public peace, health and safety, an emergency is**
20 **declared to exist, and this 2015 Act takes effect on its passage.”.**

21
